Raay Neo Pharma has officially commenced operations, marking its entry into India’s pharmaceutical sector with a focus on improving access to quality healthcare. The company plans to introduce a portfolio of more than 90 formulations spanning both acute and specialised therapy segments, alongside a pipeline of new products under development.

Founded by entrepreneur Amit Patni, Raay Neo Pharma is backed by a legacy of business experience across sectors including technology, manufacturing, finance and healthcare infrastructure. The company aims to combine scientific innovation with a patient-focused approach in delivering pharmaceutical products.

Raay Neo Pharma’s portfolio covers a wide range of therapeutic areas, including antibiotics, anti-diabetic treatments, gastrointestinal care, pain management, respiratory therapies, cardiac care, dermatology and other essential drug categories. The company is focused on providing branded generic medicines with an emphasis on safety, quality and efficacy.

The company has established a presence across several key regions, including Uttar Pradesh, Bihar, Maharashtra, Karnataka, Telangana and Delhi-NCR, among others, enabling it to reach a significant portion of the population. Its operational model integrates in-house product development with partnerships with established manufacturers, allowing for broader distribution and faster market access.

Raay Neo Pharma stated that its business strategy is built on flexibility and scalability, enabling it to respond quickly to changing healthcare needs while maintaining strict quality standards. The company also plans to invest in research and development and build a strong professional network to support long-term growth.

With its expanding product portfolio and focus on accessibility, Raay Neo Pharma is positioning itself as a new player in India’s evolving healthcare landscape.